Compare · WOK vs WST
WOK vs WST
Side-by-side comparison of WORK Medical Technology Group LTD (WOK) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both WOK and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $24.52B, about 4449.2x WOK ($5.5M).
- WOK has been more active in the news (2 items in the past 4 weeks vs 1 for WST).
- WST has more recent analyst coverage (18 ratings vs 0 for WOK).
- Company
- WORK Medical Technology Group LTD
- West Pharmaceutical Services Inc.
- Price
- -
- -
- Market cap
- $5.5M
- $24.52B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 2
- 1
- Recent ratings
- 0
- 18
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest WOK
- SEC Form 6-K filed by WORK Medical Technology Group LTD
- SEC Form 6-K filed by WORK Medical Technology Group LTD
- Large owner Hrt Financial Lp bought $40,501 worth of shares (880,456 units at $0.05) and sold $528,894 worth of shares (136,665 units at $3.87), decreasing direct ownership by 68% to 123,944 units (SEC Form 4)
- Large owner Hrt Financial Lp bought $25,548 worth of shares (268,927 units at $0.10) and sold $168,465 worth of shares (2,904,567 units at $0.06), decreasing direct ownership by 87% to 391,456 units (SEC Form 4)
- Large owner Hrt Financial Lp bought $3,849 worth of shares (48,108 units at $0.08), increasing direct ownership by 2% to 3,027,096 units (SEC Form 4)
- WORK Medical Announces 1-for-100 Reverse Stock Split Effective June 18, 2026
- Large owner Hrt Financial Lp bought $363,500 worth of shares (3,794,711 units at $0.10) (SEC Form 4)
- New insider Hrt Financial Lp claimed ownership of 949,661 shares (SEC Form 3)
- Large owner Hrt Financial Lp sold $363,617 worth of shares (3,463,022 units at $0.10), closing all direct ownership in the company (SEC Form 4)
- Large owner Hrt Financial Lp bought $239,679 worth of shares (2,261,118 units at $0.11), increasing direct ownership by 586% to 2,647,299 units (SEC Form 4)
Latest WST
- SVP & Chief Financial Officer Mcmahon Robert W. converted options into 7,149 shares and covered exercise/tax liability with 3,109 shares, increasing direct ownership by 136% to 7,021 units (SEC Form 4)
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target